Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.51 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251560 | 0.99 | CHRNA7 (0.52) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL13878623 | 0.98 | CHRNA7 (0.51) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4247357 | 0.97 | CHRNA7 (0.52) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL13878614 | 0.97 | CHRNA7 (0.50) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4241210 | 0.95 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL4241912 | 0.93 | CHRNA7 (0.48) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4239669 | 0.88 | CHRNA7 (0.53) | CHRNA7KCNH2ALDH1A1POLB | |
| SCHEMBL4243116 | 0.87 | CHRNA7 (0.53) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL13878599 | 0.86 | CHRNA7 (0.51) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL4242225 | 0.86 | CHRNA7 (0.53) | CHRNA7KCNH2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 815/4885CHRNA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.